Q-omics provides the consensus-scored RPL29P28 profile across patient tissues and cancer cell-line models. RPL29P28 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RPL29P28 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, RPL29P28 RNA expression shows 3,636 significant pathway-activity associations, with the highest sampling consensus in OV. Together, these results highlight MESO, HNSC, and OV as cancer lineages where RPL29P28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL29P28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL29P28 survival associations across molecular data types. RPL29P28 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL29P28 RNA expression–survival associations across cancer types. High RPL29P28 expression shows unfavorable associations in MESO, KIRC, UCEC and LUAD, but favorable associations in DLBC and LUSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RPL29P28 RNA expression.
This table summarizes RPL29P28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL29P28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL29P28 shows lower tumor expression in HNSC and higher tumor expression in COAD, BRCA and THCA. The HNSC box plot shows higher RPL29P28 RNA expression in normal versus tumor tissue (log2 FC = −0.058, t-test p = .022).
This table shows molecular features associated with RPL29P28 in patient tissues and cancer cell lines. In patient samples, RPL29P28 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
